CDXS

Codexis, Inc. 2010 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: Codexis, Inc.
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: Codexis develops proprietary biocatalysts (enzymes and microbes) to optimize industrial processes, primarily in the pharmaceutical and advanced biofuels sectors. The company utilizes a directed evolution technology platform to create biocatalysts that are faster, cleaner, and more efficient than conventional chemical methods.
Key Markets:

• Pharmaceuticals: Commercialized biocatalysts for drug manufacturing (e.g., sitagliptin for Merck, atorvastatin intermediates for Pfizer).
• Biofuels: Developing biocatalysts for cellulosic ethanol and biohydrocarbon diesel under a multi-year collaboration with Shell.
• Other Bioindustrials: Pursuing opportunities in carbon management, chemicals, and water treatment.

Capital Structure: Completed an Initial Public Offering (IPO) in April 2010, raising approximately $67.7 million in net proceeds. All redeemable convertible preferred stock was converted to common stock upon the IPO.

Key Financial Metrics (Year Ended Dec 31, 2010)

Metric	2010	2009	2008
Total Revenues	$107.1 million	$82.9 million	$50.5 million
Net Loss	$(8.5) million	$(20.3) million	$(45.1) million
Loss from Operations	$(7.1) million	$(18.4) million	$(44.0) million
Product Gross Margin	15%	10%	22%
Cash and Cash Equivalents	$72.4 million	$31.8 million	$21.9 million
Working Capital	$64.7 million	$16.4 million	$5.9 million
Accumulated Deficit	$(168.1) million	$(159.6) million	$(139.3) million

Revenue Composition (2010):

• Related party collaborative R&D (Shell): $66.1 million (62% of total)
• Product Sales: $32.8 million (30% of total)
• Other Collaborative R&D: $4.0 million
• Government Grants: $4.1 million

Debt and Liquidity: The company repaid its remaining financing obligations (GE Capital Loan) in October 2010. As of December 31, 2010, Codexis had no outstanding debt obligations. The company reported a net cash increase of $40.6 million for the year, driven primarily by IPO proceeds.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 29% to $107.1 million, driven by a 77% increase in product sales (due to higher sales to Merck and generics customers) and a 6% increase in Shell-related R&D revenue (due to milestone achievements and increased FTE funding).
• Improved Profitability Metrics: Net loss narrowed significantly from $20.3 million in 2009 to $8.5 million in 2010. Operating loss decreased from $18.4 million to $7.1 million.
• Cost Reductions: Research and Development (R&D) expenses decreased 4% to $52.4 million, primarily due to a $4.3 million reduction in royalty fees owed to Maxygen following the acquisition of Maxygen's IP portfolio in October 2010.
• Product Margins: Product gross margin improved to 15% from 10% in 2009, attributed to higher-margin product sales and reduced inventory write-downs.
• Balance Sheet Strength: Cash and cash equivalents more than doubled to $72.4 million following the IPO. Working capital increased to $64.7 million from $16.4 million.

Guidance, Outlook, and Risks

Management Outlook:

• Codexis does not expect to achieve profitability on an annual basis prior to at least 2012.
• The company intends to increase investment in R&D to expand its technology platform and pursue new markets.
• Revenues from the Shell collaboration are considered predictable in the near term, based on funded Full-Time Equivalent (FTE) payments and milestone achievements.

Key Risks and Contingencies:

• Customer Concentration: Shell accounted for 62% of total revenues in 2010 (down from 76% in 2009). The top five customers accounted for 85% of revenues. Loss of Shell or other major customers would materially impact the business.
• Product Concentration: 87% of pharmaceutical product revenue in 2010 was derived from three product families: atorvastatin, boceprevir, and sitagliptin.
• Collaboration Dependence: Future success in biofuels is heavily dependent on Shell's willingness and ability to commercialize the developed technologies. Shell has no obligation to purchase biocatalysts or commercialize the fuel products.
• Manufacturing Risks: The company relies on a limited number of contract manufacturers (CPC Biotech and Lactosan) for commercial-scale biocatalyst production. Disruptions could impact supply.
• Regulatory and Market Risks: Biofuels commercialization depends on government mandates, subsidies, and the availability of cellulosic biomass. Pharmaceutical revenues depend on FDA approvals for manufacturing process changes.

Unusual Items:

• Maxygen Acquisition: In October 2010, Codexis acquired Maxygen's directed evolution IP portfolio for $20.2 million, terminating royalty obligations to Maxygen.
• Restructuring: Completed restructuring activities initiated in 2009, including the closure of the Julich, Germany facility.

Investor Verification Checklist

• Shell Collaboration Status: Verify the current status of the Shell collaboration, specifically any notices regarding FTE reductions or changes to the commercialization timeline.
• Pharmaceutical Milestones: Confirm regulatory approval status for the sitagliptin manufacturing process change with Merck, as this is a key driver for future product revenue.
• Contract Manufacturing Capacity: Assess the reliability and capacity of contract manufacturers (CPC, Lactosan, Arch) to meet growing demand without disruption.
• Biofuels Commercialization: Monitor Shell's progress in building commercial-scale biofuel facilities and the impact of government policy changes on cellulosic biofuel mandates.
• Internal Controls: Review the company's progress in implementing and testing internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, following its IPO.
• Intellectual Property: Verify the scope and enforceability of the acquired Maxygen IP portfolio and any potential litigation risks regarding patent infringement.